Purple Biotech (PPBT) Competitors $2.46 -0.10 (-3.91%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. EDSA, EQ, CTXR, PHIO, ME, ALLR, AYTU, LIPO, ATHA, and NEUPShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Edesa Biotech (EDSA), Equillium (EQ), Citius Pharmaceuticals (CTXR), Phio Pharmaceuticals (PHIO), 23andMe (ME), Allarity Therapeutics (ALLR), Aytu BioPharma (AYTU), Lipella Pharmaceuticals (LIPO), Athira Pharma (ATHA), and Neuphoria Therapeutics Inc. - Common Stock (NEUP). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Its Competitors Edesa Biotech Equillium Citius Pharmaceuticals Phio Pharmaceuticals 23andMe Allarity Therapeutics Aytu BioPharma Lipella Pharmaceuticals Athira Pharma Neuphoria Therapeutics Inc. - Common Stock Edesa Biotech (NASDAQ:EDSA) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations. Does the media favor EDSA or PPBT? In the previous week, Edesa Biotech had 1 more articles in the media than Purple Biotech. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 1.89 beat Edesa Biotech's score of 1.44 indicating that Purple Biotech is being referred to more favorably in the news media. Company Overall Sentiment Edesa Biotech Positive Purple Biotech Very Positive Which has stronger valuation and earnings, EDSA or PPBT? Edesa Biotech is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$6.17M-$1.59-1.23Purple BiotechN/AN/A-$19.88M-$2.62-0.94 Do analysts prefer EDSA or PPBT? Edesa Biotech presently has a consensus target price of $21.00, suggesting a potential upside of 974.17%. Purple Biotech has a consensus target price of $33.00, suggesting a potential upside of 1,241.46%. Given Purple Biotech's higher possible upside, analysts clearly believe Purple Biotech is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, EDSA or PPBT? Edesa Biotech has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Does the MarketBeat Community believe in EDSA or PPBT? Edesa Biotech received 11 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 77.78% of users gave Edesa Biotech an outperform vote. CompanyUnderperformOutperformEdesa BiotechOutperform Votes2877.78% Underperform Votes822.22% Purple BiotechOutperform Votes1794.44% Underperform Votes15.56% Do insiders and institutionals hold more shares of EDSA or PPBT? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 22.6% of Edesa Biotech shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is EDSA or PPBT more profitable? Purple Biotech's return on equity of -55.86% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -233.69% -124.14% Purple Biotech N/A -55.86%-44.67% SummaryPurple Biotech beats Edesa Biotech on 8 of the 13 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.27M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.288.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.096.597.064.69Net Income-$19.88M$143.75M$3.23B$248.14M7 Day Performance-5.75%3.72%2.67%2.39%1 Month Performance9.33%11.01%8.82%6.05%1 Year PerformanceN/A3.87%31.44%13.60% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech2.6864 of 5 stars$2.46-3.9%$33.00+1,241.5%N/A$3.27MN/A-0.2820Positive NewsGap DownEDSAEdesa Biotech3.3611 of 5 stars$1.96+7.1%$21.00+971.4%-58.2%$13.77MN/A-1.0520Positive NewsShort Interest ↓Gap UpEQEquillium3.1587 of 5 stars$0.38flat$3.00+689.5%-46.9%$13.57M$30.41M-2.7140Positive NewsGap UpCTXRCitius Pharmaceuticals2.4254 of 5 stars$1.37+61.0%$54.50+3,878.1%-93.7%$13.46MN/A0.0020News CoverageAnalyst ForecastGap DownHigh Trading VolumePHIOPhio Pharmaceuticals3.7746 of 5 stars$2.79-5.7%$14.00+401.8%-62.2%$13.39MN/A-0.2610Short Interest ↓Analyst RevisionME23andMeN/A$0.50-35.3%N/A-94.0%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeALLRAllarity Therapeutics0.5504 of 5 stars$0.88+4.2%N/A-94.0%$13.29MN/A0.0010News CoverageAYTUAytu BioPharma1.4902 of 5 stars$2.11+5.5%N/A-36.4%$13.02M$81.66M-1.46160Short Interest ↓Gap UpHigh Trading VolumeLIPOLipella Pharmaceuticals2.3251 of 5 stars$2.91-2.7%N/A-46.4%$13.00M$536.36K-0.684Positive NewsATHAAthira Pharma2.8752 of 5 stars$0.33-8.1%$13.83+4,079.3%-87.4%$12.92MN/A-0.1240Gap DownNEUPNeuphoria Therapeutics Inc. - Common Stock2.0257 of 5 stars$6.82-0.7%$21.00+207.9%N/A$12.92M$15.66M0.00N/A Related Companies and Tools Related Companies Edesa Biotech Competitors Equillium Competitors Citius Pharmaceuticals Competitors Phio Pharmaceuticals Competitors 23andMe Competitors Allarity Therapeutics Competitors Aytu BioPharma Competitors Lipella Pharmaceuticals Competitors Athira Pharma Competitors Neuphoria Therapeutics Inc. - Common Stock Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
